About PSORT
If we can predict patient responses to individual therapies, we could then personalise treatments for each patient which could lead to better outcomes.
Psoriasis Stratification to Optimise Relevant Therapy (PSORT)
Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is a unique partnership between five UK universities: Manchester, King’s College London, Newcastle, Queen Mary University of London and Liverpool, 10 pharmaceutical and diagnostics companies, the Royal College of Physicians, the British Association of Dermatologists and the Psoriasis Association and NHS partners representing patients.
In 2013, the consortium was awarded £5 million by the UK Medical Research Council, together with an additional £2 million from industry partners, to carry out important research into psoriasis which will directly benefit patients.
The aim of the PSORT consortium is to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management.
PSORT will help to:
- optimise clinical pathways for psoriasis
- inform the management of other less accessible immune-mediated inflammatory diseases and
- deliver health care savings by efficient prescribing of biologics.